Gibson Dunn represented Apogee Therapeutics, Inc., a clinical-stage biotechnology company, in a public offering of 8,048,782 shares of common stock, including the full exercise of the underwriters' option to purchase an additional 1,097,561 shares. The post Gibson Dunn Represented Apogee Therapeutics on $345 Million Offering of Common Stock and Pre-Funded Warrants appeared first on Gibson Dunn.
